Integration of Glycolytic Metabolic Marker (GLUT1) and CD147 Expression in Progression of Prostatic Carcinoma; An Immuohistochemical Study
/ 0
- Details
- Category: Vol. 85, December 2017
- Hits: 496
Integration of Glycolytic Metabolic Marker (GLUT1) and CD147 Expression in Progression of Prostatic Carcinoma; An Immuohistochemical Study, MARWA S. ABD ALLAH and OMNEYA Y. BASSYONI
Abstract
Background: Increased glycolysis has been considered one of the characteristic features of cancer. Glucose Transporter 1 (GLUT1) plays a central role in the transport of glucose in tumor cells. CD147 is multifunctional glycoprotein overexpressed in many solids tumors.
Methods: This is a retrospective controlled study on 46 cases of prostatic carcinoma to recognize the expression of GLUT' and CD147 by irnnxunohistochernistry and to identify their correlation with different сЫniсoрathologiсal parameters.
Results: GLUT! and CD147 positive expression was detected in 25/46 (54.3%) and 29/46 (63.0%) of prostatic carcinoma, respectively. GLUT' and CD147 expression was significantly higher in prostatic carcinoma than BPH and HGPIN. Significant positive correlation between GLUT/ and CD147 immunoreactivity in prostatic carcinoma was seen. Positive GLUT' expression was statistically correlated with high Gleason score (p<).01), advanced tumor stage (p<0.01) and lymph nodes metastasis (p<0.01), distant metastasis (p< 0.05) and higher TNM stage (p=<0.01). Positive CD147 expression was statistically correlated with high Gleason score (p<0.05), advanced tumor stage (p<0.01), lymph nodes metastasis (p<0.01), distant metastasis (p<0.01), higher TNM stage (p<0.01) and perineural invasion (p<0.01).
Conclusions: Positive GLUT' and CD147 expression was significantly associated with progression and aggressiveness of prostatic carcinoma. Consequently, they might be considered as prognostic markers in prostatic carcinoma.
Key Words: GLUT! — CD147 — Prostatic carcinoma.